imlunestrant
Small moleculeapproved
Approved
Sep 25, 2025
Clinical trial activity
13 trials · 3 clinical orgs · 1 marketing orgs
Phase 1
9
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Dec 4, 2019 (NCT04188548)
Timeline
Indications
Approved for
Mechanism of action
- Estrogen receptorMODULATOR
Estrogen receptor modulator
Approval history
- approvedSep 25, 2025
Chemistry & pharmacology
Loading structure…
SMILES
Oc1ccc2c3c(cnc2c1)-c1ccc(C(F)(F)F)cc1O[C@@H]3c1ccc(OCCN2CC(CF)C2)cc1- Mol. weight
- 524.51 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095397 ↗
- ChEMBLCHEMBL5095183 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07191717 | Phase 2 | Apr 30, 2026 | University of California, Los Angeles |
| NCT07287098 | Phase 2 | Dec 31, 2025 | Eli Lilly |
| NCT05509790 | Phase 1 | Oct 9, 2022 | Eli Lilly |
| NCT05514054 | Phase 3 | Oct 4, 2022 | Eli Lilly |
| NCT05509816 | Phase 1 | Sep 12, 2022 | Eli Lilly |
| NCT05444556 | Phase 1 | Jul 7, 2022 | Eli Lilly |
| NCT05440344 | Phase 1 | Jul 5, 2022 | Eli Lilly |
| NCT05307705 | Phase 1 | May 11, 2022 | Eli Lilly, Loxo Oncology |
| NCT04975308 | Phase 3 | Oct 4, 2021 | Eli Lilly |
| NCT04991766 | Phase 1 | Aug 13, 2021 | Eli Lilly |
| NCT04840888 | Phase 1 | Apr 26, 2021 | Eli Lilly |
| NCT04647487 | Phase 1 | Dec 21, 2020 | Eli Lilly |
| NCT04188548 | Phase 1 | Dec 4, 2019 | Eli Lilly |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 12 | 12 | 3 | 2019 |
| Loxo Oncology | For profit | 1 | 0 | 1 | 2022 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2026 |
3 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Eli Lilly | For profit | MKTG | Sep 25, 2025 |